RxDoctor Payments DataLook up a doctor →

Raja Sivamani

Dermatology · Sacramento, CANPI 1811197478

Payments from drug & device makers

$11,849,930in general payments, 2019–2025

Across 2,500 payments — averaging $4739.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4.6M
  • Amgen$1.5M
  • Incyte Corporation$1.2M
  • Boehringer Ingelheim$884K
  • E.r. Squibb & Sons, L.L.C.$776K
  • Janssen Research & Development, LLC$647K
  • plus $2.2M from 31 others
$194,518in research payments, 2019–2025

Across 39 payments — averaging $4987.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nielsen Biosciences, Inc.$168K
  • Eli Lilly$20K
  • AbbVie$4K
  • Regeneron$2K
  • Novartis$324

What the payments were for

  • Consulting fees$249,70213%
  • Speaking & faculty fees$1,396,90874%
  • Travel & lodging$198,99511%
  • Food & beverage$34,9152%
  • Education$2290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,849,930 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$854,081
Medicare patients
2,005
Services billed
11,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab30$108,252
CibinqoAbrocitinib14$96,712
Cosentyx Sensoready (2 Pens)Secukinumab12$85,145
Taltz AutoinjectorIxekizumab13$84,142
SotyktuDeucravacitinib11$70,447
RasuvoMethotrexate/Pf16$12,325
Ivermectin19$3,978
Clobetasol Propionate47$1,454
Fluocinonide20$1,452
Fluorouracil17$1,102
Betamethasone Dipropionate24$922
Ketoconazole43$636
Doxycycline Hyclate26$414
Doxepin Hcl26$391
Minoxidil60$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerCibinqo$401,342$96,71214 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$775,962$70,44711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.

Other dermatology in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →